Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) T.ATE

Alternate Symbol(s):  ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


TSX:ATE - Post by User

Comment by MrMugsyon Feb 01, 2023 5:56pm
319 Views
Post# 35260876

RE:RE:2 Weeks away from Q3 update

RE:RE:2 Weeks away from Q3 update
Doccole wrote:

The only consistency is inconsistency.  

I've been hearing about the iBD for years.

I've been hearing about "getting excited" "put us on the map" for years.

can't wait for the next "pivot"

I will be surprised if it even starts a phase II trial.  i hope I don't lose all my money, but I have 0 hope for this stock and company.  

Just remember Doccole ... you don't have to believe anything.
That's your right.
That's how you end up picking winners and losers.
You can do whatever you want - and - you can believe whatever you want.

----------------------------

Fact is ... drug development sucks in general.
It's a tough game.
If you know of a company that created a drug and got it to market quickly - stick with it - maybe you have a real winner there.

----------------------------

Why has acute taken so long ?  Now we know that they chose a modified formulation but don't expect anyone to tell you that early ... just not the way drug development works.

Why is IBD late?  Why has it been moved from Q2 to Q3 then to Q4 and now to Q1 2023 ?
That we don't know.
And no one is willing to tell you.
Think it's because they don't like you ?  Think again.
Is it related to reformulation? 
Are there additional tests required to prove the best candidate?
Is it the same old technology or something brand new ?
No one is going to tell you - but - rest assured - something is up.
Good or bad - something is up - and - they can't talk about it.

What about chronic ?
Does it have a chance ?
Some say no way !
Others say it's always been moving forward.
Are they going to tell you?  Good or bad ?
No ... they're not going to tell you until they can.  That's drug development.

Why do we have an Antiviral drug based on Indomethacin ?
What are they doing with it ?
Don't expect an answer - that's just drug development for you.

So ... while I wait for 2023 (and I'm sure there will be other slow developments ...
Just remember this ...
No one is going to tell you early.
It just isn't the way drug development works.

-----------------------

Now ... you decide if you want to stay or exit your position.
You decide if this is the place to be - OR - the place you don't want to be.
You decide !

It's no one's business to tell you what to do - that's all you my friend !!!!




<< Previous
Bullboard Posts
Next >>